Cardinal Health and Bayer sign 15-year contract manufacturing agreement for Xofigo
Cardinal Health (NYSE: CAH) and German drug major Bayer (BAYN: DE) have signed a 15-year agreement for the contract manufacturing of Xofigo (radium Ra 223 dichloride).
Cardinal Health will build a dedicated facility in Indianapolis specifically for the manufacturing of Xofigo, the output of which will primarily be distributed in the USA and Canada. It will be supported by around 85 employees, including specialized manufacturing roles, chemists, engineers and other professional positions.
The manufacturing facility will be situated near Cardinal Health's existing Indianapolis radiopharmacy, one of the two US locations authorized by Bayer HealthCare to distribute Xofigo. Cardinal Health is the sole distributor of Xofigo in the country.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze